F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2) agonists. As such, they are believed to be potentially useful for the treatment of rheumatoid arthritis, amyotrophic lateral sclerosis, frontotemporal dementia, multiple sclerosis, prion disease, stroke, Parkinson's and Alzheimer's disease.

Pfizer Inc. has patented new gastric inhibitory polypeptide receptor (GIPR) antagonists reported to be potentially useful for the treatment of type 2 diabetes and obesity.

A recent Ensem Therapeutics Inc. patent details the discovery of tricyclic derivatives acting as GTPase KRAS (mutant) inhibitors for use in the treatment of cancer.